Ondine Biomedical Inc., a Canadian company specializing in antimicrobial photodisinfection, has secured its first commercial deal with an NHS trust in the UK. The company’s Steriwave technology has been adopted by the Pontefract and Pinderfields hospitals, following a successful 500-patient elective hip and knee surgical quality initiative at Pontefract.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed excitement about this milestone, which comes after demonstrating positive outcomes and favorable health economics. The company aims to develop a business case with the York health economics group and Mid Yorkshire for broader NHS adoption, leveraging the successful results.
Steriwave’s adoption in the UK is part of Ondine’s growing commercial momentum. The technology is now deployed in eight new healthcare facilities, spanning 22 facilities in Canada and expanding its presence in the UK and Spain. This success is attributed, in part, to Steriwave’s effectiveness in reducing the need for antibiotics, as demonstrated in a UK study, and its alignment with antimicrobial resistance efforts.
Moving forward, Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials. The company’s innovative approach to antimicrobial photodisinfection positions it as a promising solution in the fight against antibiotic resistance and healthcare-associated infections.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Ondine Biomedical’s Steriwave Gains Traction in UK Healthcare Facilities.